Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.27 USD
−1.04 B USD
4.38 B USD
179.82 M
About Catalent, Inc.
Sector
CEO
Alessandro Maselli
Headquarters
Somerset
Website
Founded
1933
FIGI
BBG005XR47P5
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
C
CTLT4851488
Catalent Pharma Solutions, Inc. 5.0% 15-JUL-2027Yield to maturity
5.21%
Maturity date
Jul 15, 2027
C
CTLT5265739
Catalent Pharma Solutions, Inc. 3.5% 01-APR-2030Yield to maturity
4.07%
Maturity date
Apr 1, 2030
C
CTLT5130036
Catalent Pharma Solutions, Inc. 3.125% 15-FEB-2029Yield to maturity
3.70%
Maturity date
Feb 15, 2029
C
CTLT4851489
Catalent Pharma Solutions, Inc. 5.0% 15-JUL-2027Yield to maturity
—
Maturity date
Jul 15, 2027
Explore more bonds
Frequently Asked Questions
The current price of CTLT is 59.72 USD — it has increased by 0.20% in the past 24 hours. Watch Catalent, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Catalent, Inc. stocks are traded under the ticker CTLT.
CTLT stock has fallen by −0.35% compared to the previous week, the month change is a −2.22% fall, over the last year Catalent, Inc. has showed a 48.74% increase.
We've gathered analysts' opinions on Catalent, Inc. future price: according to them, CTLT price has a max estimate of 63.50 USD and a min estimate of 63.00 USD. Watch CTLT chart and read a more detailed Catalent, Inc. stock forecast: see what analysts think of Catalent, Inc. and suggest that you do with its stocks.
CTLT reached its all-time high on Sep 9, 2021 with the price of 142.64 USD, and its all-time low was 18.92 USD and was reached on Feb 10, 2016. View more price dynamics on CTLT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CTLT stock is 1.57% volatile and has beta coefficient of 0.41. Track Catalent, Inc. stock price on the chart and check out the list of the most volatile stocks — is Catalent, Inc. there?
Today Catalent, Inc. has the market capitalization of 10.71 B, it has increased by 0.15% over the last week.
Yes, you can track Catalent, Inc. financials in yearly and quarterly reports right on TradingView.
Catalent, Inc. is going to release the next earnings report on Feb 11, 2025. Keep track of upcoming events with our Earnings Calendar.
CTLT earnings for the last quarter are −0.13 USD per share, whereas the estimation was 0.05 USD resulting in a −387.66% surprise. The estimated earnings for the next quarter are 0.14 USD per share. See more details about Catalent, Inc. earnings.
Catalent, Inc. revenue for the last quarter amounts to 1.02 B USD, despite the estimated figure of 1.06 B USD. In the next quarter, revenue is expected to reach 1.11 B USD.
CTLT net income for the last quarter is −129.00 M USD, while the quarter before that showed 23.00 M USD of net income which accounts for −660.87% change. Track more Catalent, Inc. financial stats to get the full picture.
No, CTLT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 16.90 K employees. See our rating of the largest employees — is Catalent, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Catalent, Inc. EBITDA is 645.00 M USD, and current EBITDA margin is 14.47%. See more stats in Catalent, Inc. financial statements.
Like other stocks, CTLT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Catalent, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Catalent, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Catalent, Inc. stock shows the neutral signal. See more of Catalent, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.